Form 4: Cognition Therapeutics CMO Vests 65,000 Shares

Cognition Therapeutics' Chief Medical Officer, Anthony Caggiano, acquired 65,000 shares of common stock through PSU vesting, while 20,280 shares were withheld for tax obligations.

Summary

• Anthony Caggiano, Chief Medical Officer of Cognition Therapeutics Inc. (CGTX), acquired 65,000 shares of common stock on December 18, 2025.
• These shares were earned upon the vesting of performance stock units (PSUs) granted on February 14, 2024, representing the remaining 50% of the total shares subject to the PSUs.
• Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon the achievement of certain performance goals.
• Concurrently, 20,280 shares were disposed of by the Issuer to cover tax withholding obligations related to the PSU vesting, at a price of $1.5 per share.
• Following these transactions, Anthony Caggiano beneficially owns 507,993 shares of Cognition Therapeutics common stock directly.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The vesting of PSUs indicates performance goals were met, and the executive increased their net beneficial ownership, aligning interests with shareholders. The tax withholding is a neutral, administrative event.

Positives

• The vesting of performance stock units indicates that certain performance goals set by the company were achieved, leading to the award of shares to the Chief Medical Officer.
• Anthony Caggiano increased his direct beneficial ownership of company stock by 44,720 shares (65,000 acquired 20,280 withheld for taxes), aligning his interests further with shareholders.

Negatives

• A portion of the vested shares (20,280 shares) was withheld by the company to cover tax obligations, rather than being retained by the officer or sold on the open market by the officer for personal liquidity.

Future Outlook

The filing does not contain any explicit forward-looking statements or guidance beyond the completion of the described transaction.

Industry Context

Insider transactions, particularly the vesting of equity awards like PSUs, are common in the biotechnology and pharmaceutical industries. These awards are a standard component of executive compensation packages, designed to align management incentives with long-term shareholder value creation and reward the achievement of strategic performance milestones. The withholding of shares for tax purposes is a routine administrative process for such equity compensation.

Comparison to Industry Standards

• The structure of performance stock units (PSUs) tied to performance goals is a widely adopted practice in executive compensation across the biotech and broader corporate landscape, similar to compensation structures seen at companies like Pfizer, Moderna, or Biogen, which often use a mix of base salary, cash bonuses, and equity awards (including PSUs and stock options) to incentivize executives.
• The withholding of shares to cover tax obligations upon vesting is a standard administrative procedure for equity awards, consistent with practices observed at virtually all publicly traded companies that grant stock-based compensation.

Stakeholder Impact

• Shareholders: The increase in the Chief Medical Officer's direct beneficial ownership aligns management's interests with shareholder value. The achievement of performance goals for PSU vesting could be seen as a positive indicator of company progress.
• Employees: This transaction reflects the company's compensation structure for executives, which may influence broader employee compensation strategies and morale.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the vesting of performance stock units and subsequent tax withholding. While it indicates the achievement of performance goals and an increase in the executive's beneficial ownership, it does not provide new material information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. It is a standard compensation event.

Keywords

Cognition Therapeutics, CGTX, Form 4, Insider Transaction, Performance Stock Units, PSU Vesting, Chief Medical Officer, Anthony Caggiano, Stock Award, Executive Compensation